NeurAegis

NeurAegis is a preclinical-stage neuropharmaceutical company dedicated to developing breakthrough treatments for neurological disorders. Founded in 2016, our initial focus was on developing first-in-class, novel protease inhibitors for mild traumatic brain injury (concussion), for which there are currently no FDA-approved treatments.